Physician profile
Maaman Bashir
NPI 1225432917
$4,418.58
in general payments reported to CMS, 2019-2025
17 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $479 · 2022: $1,164 · 2023: $904 · 2024: $795 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,774.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,252.42 | 2021-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,114.79 | 2021-2025 | Enbrel, Tavneos, Krystexxa |
| Ucb, INC. | $676.39 | 2021-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $278.41 | 2021-2024 | Benlysta |
| Mallinckrodt Hospital Products INC. | $273.21 | 2023-2025 | Acthar |
| Travere Therapeutics, INC. | $196.34 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $111.43 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.53 | 2021-2022 | |
| Janssen Biotech, INC. | $87.93 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Genentech USA, INC. | $79.07 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $67.41 | 2024-2025 | Orencia |
| Novo Nordisk INC | $42.43 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $36.63 | 2021-2022 | |
| Akebia Therapeutics INC | $27.88 | 2025 | Vafseo |
| Organon LLC | $26.66 | 2023-2024 | Renflexis |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22.57 | 2023 | |
| Nxstage Medical, INC. | $14.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maaman Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.